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14.1. Photosensitization and photosensitizers 
14.1.1 What is photosensitization and how it proceeds 
Photosensitization is a response to light that is mediated by a light-absorbing molecule, 
called a ‘photosensitizer’, which is not the final target and is not destroyed during the process. 
When it absorbs a photon, the photosensitizer alters another molecule, called ‘substrate’ or 
‘acceptor’, that can be part of a chemical system or a living organism. Both photosensitizer 
and light are required for photosensitization to occur, while generally light levels and 
sensitizer nature and concentration are such that individually they have no main effect on the 
system or organism. 
Insert Fig. 1 here 
The first step of the process is absorption of light by a photosensitizer P to produce an 
excited state (P*). In the presence of oxygen, P* undergoes internal reactions that ultimately 
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result in the chemical alteration of the substrate S. As shown in Fig. 14.1, P* can either react 
directly with the substrate (Type I reaction) or with oxygen (Type II reaction).  
Type I reactions result in either hydrogen atom or electron transfer, yielding radicals or 
radical ions, with the excited sensitizer generally acting as an oxidant. The radical species that 
are formed are often highly reactive, such as superoxide and hydroxyl radicals.  
Type II reactions mainly lead to excited state singlet oxygen (1O2). Singlet oxygen then 
reacts with the substrate to generate oxidized products. For most photosensitizers, the excited 
singlet state has very short lifetime and rapidly undergoes intersystem crossing, that is a 
transition to a slightly lower energy level involving an electron spin flip. The spin flip leads to 
a triplet energy state. Transitions between triplet and singlet energy states are forbidden. 
Consequently the excited triplet state generally has a longer lifetime than an excited singlet 
state, and hence is more likely to enter into an energy transfer reaction. Singlet oxygen is a 
highly reactive oxygen species that has an excited state lifetime of a few microseconds in 
most biological environments.  
Type II (singlet oxygen) processes are favored over Type I (radical) processes by lower 
substrate concentration and higher oxygen concentration. Most important photosensitization 
reactions, either spontaneous or induced ones, occur via Type II processes. 
It is also worth noting that oxygen is an important reactant in most photosensitization 
reactions, whether it is part of the initial reaction with the excited photosensitizer (Type II), or 
gets involved later, transforming the initial radicals into oxidized products (Type I). 
 
The PhotoDynamic Therapy (PDT) is a form of treatment that requires oxygen for its 
therapeutic effect. This implies that in PDT a photosensitizer, light and oxygen are all 
required. The Type II reaction pathway is expected to be the main one, but Type I reactions 
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involving oxygen may also be implied. PDT has been investigated and developed mostly for 
the treatment of cancer and precancereous lesions (actinic keratosis). However, various other 
applications are under investigation (e.g. the treatment of age-related macular degeneration). 
More details can be found in the following (Subsection 14.1.5). 
14.1.2 Basic properties of photosensitizers 
Let us now examine more in detail excitation and de-excitation processes of a generic 
molecule to highlight properties that are key for an efficient photosensitizer. 
Insert Fig. 2 here 
Molecules that absorb light and are excited to the first singlet state subsequently lose the 
acquired energy through either radiative or radiationless decay (Fig. 14.2). When the higher 
vibrational levels of the lower electronic state overlap the lower vibrational levels of the 
higher electronic state (i.e. the nuclear configurations and energies of the two electronic states 
are identical), vibrational coupling occurs, and crossover from a higher to a lower excited 
singlet state is possible. This is a very fast process (10-12 s), known as internal conversion.  
If the vibrational levels of the two electronic states are separated, a radiative transition 
(fluorescence) may also occur from the lowest vibrational level of the higher electronic state 
to any vibrational levels of the lower electronic state. Emission takes place from thermally 
equilibrated excited states, namely from the lowest vibrational level of the lowest excited 
singlet state, because relaxation from the excited vibrational levels (through emission of 
infrared quanta or as kinetic energy lost during collisions) is much faster than emission (10-
14−10-12 s vs  ≈10-9-10-8 s). The transition may lead to any vibrational levels of the ground 
state because, even though the lifetime of the fluorescent molecule is of the order of 10–9-10-8 
s, the actual electronic transition occurs much faster (10-15 s), so that vibrational relaxation 
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cannot take place during the transition. Thus, the emission spectrum generally consists in a 
broad band, not a narrow line. Moreover, for biomolecules, the emitted photons have most 
often frequency in the ultraviolet (UV) or visible range. Following radiative transition, the 
molecule undergoes vibrational relaxation to the lowest vibrational level (10-14−10-12 s). 
Which one of the two deactivation mechanisms is favored depends on the number of 
vibrational levels and the difference in energy between the vibrational levels of the two 
electronic states. The closer they are, the more likely internal conversion will occur. This is 
the reason why molecules with no rigid skeleton, such as aliphatic molecules, rarely exhibit 
fluorescence, while aromatic molecules, with their rigid ring structures are usually 
characterized by strong fluorescent emission.  
For the same reason, fluorescence occurs almost always only as a deactivation mechanism 
between the first excited singlet state and the ground state. Higher excited states are generally 
much closer to each other. Hence, internal conversion is favored and precludes the possibility 
of fluorescence emission. Consequently, different from the absorption spectrum, the emission 
line shape is made of just one band. The presence of more than one band in the spectrum of 
isolated molecules indicates that more than one species is fluorescing. This does not 
necessarily mean that the emitting molecules have different chemical structure. Actually, 
when the emitting molecules interact with a complex environment or aggregate, distinct 
fluorescence bands can be observed, corresponding to different binding sites, states of 
aggregation, etc.  
A feature that is commonly used to characterize each deactivation process is its quantum 
yield. Let us for example consider deactivation by fluorescent emission. The quantum yield of 
fluorescence φf is the fraction of excited molecules that fluoresce. It can be expressed as:  
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where: kf is the rate constant for fluorescence (i.e. the probability that the excited molecule 
will fluoresce); Σkd is the sum of the rate constants for all radiationless deactivation 
mechanisms of the first excited singlet state; τf = (kf + Σkd)-1 is the lifetime of the first excited 
singlet state, that is the average time the molecule spends in the excited state; τοf = (kf)-1 is the 
radiative lifetime, that is the average time the molecule would spend in the excited state if 
fluorescence were the only deactivation mechanism. 
As described previously, when molecules are in the lowest vibrational state of the first 
excited singlet state, de-excitation may also occur via intersystem crossing, which is a 
transition to a slightly lower energy level involving an electron spin flip. The spin flip leads to 
a triplet energy state. Transitions between triplet and singlet energy states are forbidden, and 
consequently the excited triplet state generally has a longer lifetime than an excited singlet 
state, and hence is more likely to enter into an energy transfer reaction. However, de-
excitation of the triplet state may also occur through long-living (≥10-3 s) photon emission 
(phosphorescence). 
Photosensitizers are molecules that efficiently transfer an electron to or from another 
molecule, or transfer their excitation energy to other molecules (typically molecular oxygen). 
In most cases, the reason why some molecules are so effective at electron transfer and/or 
energy transfer is that they very efficiently populate their excited triplet states. The relatively 
longer lifetime of the triplet state allows more time for energy and/or electron transfer to 
occur. So, most highly effective photosensitizers are characterized by high quantum yields for 
 6 
the production of their excited triplet state, which is a competing mechanism against radiative 
decay (fluorescence).  
The action spectrum is often used to quantify the efficiency of a photosensitizer to 
produce a specific effect (e.g., cell killing). An action spectrum shows the dependence of the 
measured effect on the excitation wavelength. As an example, the action spectrum for the 
photochemical inactivation of cells can be found by measuring the dose of light necessary for 
inactivating the same cell fraction at different wavelengths, and plotting the results as required 
dose vs excitation wavelength. 
14.1.3 Photosensitizer interactions with biological tissues 
Ground-state molecular oxygen has low reactivity and diffuses rapidly through most 
biological environments, including cell membranes, while singlet oxygen reacts with several 
biological substrates. Efficient interaction occurs with certain amino acids in proteins (e.g., 
tryptophan, tyrosine, histidine), DNA and RNA (guanine bases), as well as a variety of 
unsaturated lipids (including cholesterol and unsaturated fatty acids). On the contrary, no 
significant effect is produced on carbohydrates. This reactivity limits the ability of singlet 
oxygen to diffuse great distances. Thus, Type II photosensitization can affect biological 
substrates only at a moderate distance, up to fractions of micrometers, from the 
photosensitizer itself.  
In turn, hydroxyl radicals generated by Type I reactions, are so reactive that they typically 
interact with the first molecule they get close to, limiting their effects to the site where they 
are generated.  
Therefore, for both types of reactions, the photosensitizer localization is of key importance 
to determine and control biological effects. Some selectivity towards the environment can 
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inherently be provided by the sensitizer itself. For example, if it is highly soluble in lipids, it 
will likely tend to localize in the cell membrane rather than in its cytoplasm. However, 
stronger and more selective targeting can be achieved attaching the sensitizer to a target-
specific molecule. 
The heat released during photosensitization processes may also be used to cause selective 
damage, in a process that is named photothermal sensitization. 
14.1.4 Types of photosensitizers 
Photosensitizers can either be naturally present in living systems (i.e., endogenous) or 
generated by an external source and administered to the living system (i.e., exogenous).  
Endogenous photosensitizers include molecules such as porphyrins or chlorophyll. Under 
native conditions, their potential photosensitizing effects are not apparent, either because their 
concentrations are too low, or because they form complexes that inhibit photosensitization 
reactions. Exogenous photosensitizers include many varieties of dyes and biomolecules. 
Some are natural products (e.g., from plants), while others are synthesized for different 
applications (e.g., medical or agricultural ones).  
A third interesting type of photosensitizers also exists, namely exogenously induced-
endogenous photosensitizers. These photosensitizers are intermediate between endogenous 
and exogenous ones. A precursor is administered, which is not active. The metabolic activity 
of the receiving organism then transforms it into a fully functional photosensitizer.  
Porphyrin-based photosensitizers 
Hundreds of different compounds act as photosensitizers for biological systems. They are 
often classified based on their chemical structure.  
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Porphyrin-based photosensitizers deserve particular attention as they include important 
endogenous sensitizers, as well as exogenously induced endogenous sensitizers and 
exogenous sensitizers that are approved for clinical PDT and/or for fluorescence-based cancer 
detection (Berg et al 2005, Sternberg and Dolphin 1998). 
Insert Fig. 3 here 
Porphyrins contain four pyrrole subunits linked by methine bridges (Fig. 14.3). 
Tetrapyrroles are naturally occurring pigments, involved in many biological processes. They 
include the metallopigments heme (the prosthetic group of proteins like hemoglobin), vitamin 
B12, and chlorophyll. All these compounds allow coordination of different metals at the ring 
centre. While the presence of the metal prevents photosensitization, its removal yields 
efficient photosensitizers. Most efficient porphyrin-based photosensitizers generally lack 
coordinated metal ions. On the other hand, several metallophotosensitizers for clinical 
purposes have been developed along the years, balancing opposing needs. In most cases, they 
are less effective than they would be in the absence of metal ions; however they have other 
properties of basic importance for clinical applications, like improved solubility and stability. 
Except for methylene blue, all clinically-approved photosensitizers used in PDT are 
porphyrin-based sensitizers, with substituents in the peripheral positions of the pyrrole rings, 
on the methine bridges that link the pyrrols, and/or with coordinated metals. These derivates 
are synthesized to influence the water/lipid solubility, amphiphilicity, and stability of the 
compounds, which in turn determine their biodistribution and pharmacokinetics. 
Hematoporphyrin was the first photosensitizer applied in humans. In the early 1960s, 
attempts to purify it led to Hematoporphyrin Derivative (HpD), a mixture of monomers and 
oligomers. A more purified version (Photofrin®) was then produced and commercialized. The 
idea was to enrich the solution in oligomers that were recognized as the tumor-localizing 
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fraction of the porphyrin mixture. HpD and Photofrin are far from being ideal 
photosensitizers for use in PDT. Their composition is not accurately reproducible. They have 
long half-life in the body, leading to undesired skin and eye photosensitivity for 4-6 weeks 
after injection. Even more important limitations are due to their non-ideal spectral properties. 
Their absorption spectrum consists of a strong absorption Soret band in the UV (350-400nm) 
and four much weaker Q-bands in the visible range. Tissue attenuation is strong at short 
wavelengths (UV and blue-green), mostly due to melanin and hemoglobin. Thus, the longest 
wavelength (red) Q-band is exploited for PDT when deep tissues need to be reached with 
enough light for an effective treatment, even though this provides weak photosensitizer 
absorption. Notwithstanding all these limitations, porphyrin derivatives are approved for a 
wide range of clinical applications and a large number of patients have been treated up to now.  
It is interesting to note that, for diagnostic purposes, shorter wavelengths (within the Soret 
band) have often been applied, favoring efficient excitation at the expenses of deep tissue 
penetration. This choice is particularly suitable when surface targets are investigated, as in the 
case of skin pathologies or mucosal lesions that can be reached endoscopically. 
Increased absorption in the red-infrared range can be achieved by reducing one (chlorines) 
or two (bacteriochlorins) double bonds in the conjugated ring structure. Specifically, meso-
tetra(hydroxyphenyl)chlorin (m-THPC, Temoporfin, Foscan®) is a chlorine that has been 
approved for the clinical treatment of head and neck cancer. 
The possibility to develop new photosensitizers with higher absorption at long wavelengths 
is actively being explored. However, it has to be taken into account that an upper wavelength 
limit exists around 850-900 nm, due to the minimum energy photons need to absorb to induce 
singlet oxygen formation. Moreover, due to water absorption, tissue attenuation above 900 
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nm raises considerably. Thus, the therapeutic window for effective in vivo treatments extends 
approximately from 600 to 800 nm.  
14.1.4.1. Non porphyrin-based photosensitizers 
A variety of endogenous and exogenous sensitizers with non porphyrin structure exists 
(Wainwright 1996). Just few examples are mentioned here, as they are much less investigated 
and used for PDT and fluorescence detection of pathologic lesions than porphyrins and 
related compounds. 
Cyanines are synthetic dyes, originally developed to extend the sensitivity range of 
photographic emulsions. Phthalocyanines, in particular, are macrocyclic compounds, 
featuring four pyrrole-like subunits, similar to porphyrins (Fig. 14.3).  They have intense 
blue-green color (corresponding to strong absorption in the red) and are widely used in dyeing. 
Phthalocyanines form coordination complexes with most elements. These complexes are also 
intensely colored and used as dyes or pigments (e.g., in paints). Substitution can increase 
solubility and shift the absorption to longer (near-infrared wavelengths), with advantage for in 
vivo applications.  
Hypericin is isolated from the plant known as St. John's wort (Hypericum perforatum) and 
is possibly the most powerful photosensitizer present in nature, with quantum yields of singlet 
oxygen formation up to 0.8. It acts through both Type I and Type II reactions and its spectral 
properties are not too unfavorable, with peak absorption in the red (around 595 nm). It has 
been tested clinically for several cancer indications, and also for the detection of bladder 
cancer. Furthermore, Hypericin has antibiotic and antiviral properties. 
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14.1.4.2. Precursor-induced photosensitizers 
The most common couple of precursor/sensitizer is δ-aminolevulinic acid/Protoporphyrin 
IX (Collaud et al 2004, Berg 2005).  
Protoporphyrin IX (PpIX) is an intermediate in biosynthetic pathways to produce 
cytochromes, hemoglobin (the oxygen-binding protein in red blood cells), and myoglobin 
(which binds oxygen in muscles). Under normal conditions, free PpIX is present at too low 
concentration to produce photosensitization reactions. However, if excess δ-aminolevulinic 
acid (ALA) is provided (either systemically or topically, depending on application), PpIX 
may accumulate, causing photosensitization reactions. The administration of ALA-hexyl ester 
is approved for the therapy of bladder cancer, while ALA-methyl ester is approved for the 
treatment of Bowen’s disease, actinic keratosis and basal cell carcinoma.  
PpIX is also characterized by intense red fluorescence, when excited by violet light. Thus, 
it is also effectively applied for the detection of lesions to be treated with PDT, and for the 
identification or surgical resection margins. 
14.1.5 Why is photosensitization important? 
Photosensitization reactions affect our lives in many different ways. For example, they are 
used in synthetic chemistry to produce products that would be much more difficult or 
expensive to produce by other means. However, in the following we will focus mostly on 
therapeutic applications.  
14.1.5.1. PDT and detection of tumors 
In the last decades photosensitizers and light have extensively been tested and applied to 
treat malignant tumors (e.g., in the bladder, prostate, lung, brain) and to remove through PDT 
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other unwanted tissue (e.g., in the precancerous condition represented by Barrett’s esophagus) 
(Hamblin and Mroz 2008, MacDonald and Dougherty 1999, O'Connor et al 2009).  
The sensitizer is most often administered systemically and reaches both healthy and 
diseased tissues. The possibility to perform an efficient photodynamic therapy relies on the 
fact that the sensitizer tends to accumulate more and is retained longer in the tumor than in the 
surrounding healthy tissue, due to concurrent factors that differentiate normal from pathologic 
tissue (metabolism, angiogenesis, etc.). This makes the latter more prone to the photodynamic 
action, when irradiated with light of suitable wavelength. Obviously, also selective irradiation 
of the area of interest can contribute to limit undesired photodynamic actions in healthy tissue. 
When ALA/PpIX PDT is performed, therapeutic benefit comes also from the fact that the 
production of PpIX occurs more efficiently in lesions than in surrounding normal tissue. 
One of the most interesting phenomena observed in the PDT of cancer is also an advantage 
over other therapeutic modalities: PDT has the potential to induce strong and long lasting 
anti-tumor immune response (Canti et al 1994, Korbelik et al 1999). 
Besides therapeutic purposes, the fluorescence properties of photosensitizers may be 
effectively exploited for the detection of cancers. For example, intravesical instillation of 
ALA-hexyl ester (Hexvix®) is approved for the detection of bladder cancer, in particular for 
carcinoma in situ, which is generally difficult to detect. PPIX fluorescence guided resection of 
bladder cancer has also shown promise for treatment purposes. Similarly, systemic 
administration of ALA (Gliolan®) is approved for intra-operative fluorescence guided 
detection and resection of malignant glioma. 
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14.1.5.2. PDT in ophthalmology 
PDT was originally introduced as a modality for cancer treatment, but one of its most 
successful applications is certainly the treatment of choroidal neovasculature associated with 
age-related macular degeneration (AMD). PDT with Verteporfin (Visudyne®), a 
benzoporphyrin derivative, was the first therapy approved for subfoveal lesions. Since 2000, 
it spared hundreds of thousands of eyes from blindness and is now a standard treatment for 
AMD (Lim 2002, Bessler 2004). The drug is injected intravenously and, 15 minutes after the 
start of the infusion, the retina is irradiated with 690 nm light (50 J/cm2). At the time of 
irradiation, the drug is still mostly localized in the blood vessels of the pathologic choroidal 
neovasculature and causes their occlusion. 
14.1.5.3. PDT in dermatology 
Dermatologic pathologies are especially suitable for PDT, as they are exposed. So local 
administration of the photosensitizer is often applied and light can easily be conveyed to the 
treatment site.  
One of the main applications of PDT in dermatology is the treatment of non-melanoma 
skin cancer and its precursors, such as actinic keratosis. However, several other pathologic 
conditions have been successfully treated with PDT, including inflammatory and immune 
diseases (e.g., psoriasis) as well as infections (e.g., human papilloma virus) (Choudhary et al 
2009, Nestor et al 2006). ALA-PDT seems to be a safe and a suitable alternative for a variety 
of conditions encountered in dermatology. The technique is effective in patients of all ages 
and typically results in better clinical and cosmetic outcomes than conventional surgery, 
which is an important benefit, when exposed lesions are treated, especially on the head and 
neck.  
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14.1.5.4. PDT of cardiovascular diseases 
Atherosclerosis and its complications are a leading cause of morbidity and mortality in 
industrialized countries. In cardiovascular medicine, PDT has been applied to treat 
atherosclerosis and to inhibit the restenosis due to intimal hyperplasia that often occurs after 
vascular interventions.  
Phase I trials were performed in the last decade, suggesting that good therapeutic response 
can be achieved and that the therapy is well tolerated (Rockson et al 2000, Kereiakes et al 
2003). 
14.1.5.5. Antimicrobial PDT  
From the beginning of the 20th century onwards, many reports were published on the 
photodynamic inactivation of various species of bacteria, fungi, and viruses. 
More recently, fundamental differences in susceptibility to PDT were observed between 
Gram (+) and Gram (-) bacteria. In general, neutral or anionic photosensitizes are efficiently 
bound to and allow the photodynamic inactivation of Gram (+) bacteria (Malik et al 1992, 
Merchat et al 1996), but they are unable to photoinactivate Gram (-) bacteria. The latter result 
can be achieved in various ways. The permeability of the cell outer membrane can be 
increased administering substances, such as EDTA, together with the photosensitizer. 
Alternatively one can use a cationic photosensitizer molecule with an intrinsic positive charge, 
or polycationic sensitizer conjugates formed from polymers such as polylysine.  
The demonstration of efficient photoinactivation of several classes of microorganisms, the 
fact that antibiotic resistant bacteria are as susceptible to photodynamic inactivation as their 
naive counterparts (Wainwright et al 1998), together with the increasing appearance of 
 15 
antibiotic resistance amongst pathogenic bacteria, suggest that PDT may be a useful tool to 
treat infectious diseases (Hamblin et al 2004) and will likely be a growing application of PDT.  
14.1.5.6. Photo-activated pesticides 
Photoresponsive systems are widespread in nature, and life processes such as 
photosynthesis and vision are linked with structural changes of molecules caused by sunlight. 
Similar photochemical transformations can be employed to make synthetic agrochemicals and 
drugs active, or to control their bioavailability at the site of action. Photo-activated pesticides 
have been used as insecticides, fungicides and herbicides. Their activity relies on preferential 
accumulation of photosensitizers (e.g., porphyrins and xanthenes) in target organisms and on 
phototoxicity elicited by sunlight illumination (Ben Amor and Jori 2000, Heitz and Downum 
1987). 
Photo-activated pesticides are known as green pesticides as they are environment friendly: 
they exert their toxic action selectively on the target where they preferentially localize, 
degrade themselves and cause no contamination of the environment. 
14.2. Fluorescence imaging of photosensitizers in small animals 
In section 14.1, it was pointed out that the activation of photosensitizers requires radiation 
of proper wavelength. Hence, the design of a PDT treatment should consider the absorption 
spectrum of the drug and the optical properties of biological tissues at the activation 
wavelength. A wealth of papers deals with PDT dosimetry, i.e. mathematical models that take 
into account the scattering (μ’s) and the absorption (μa) properties of the tissue in order to 
predict the amount of light absorbed by the photosensitizer. The scattering μ’s, in fact, 
modulates the power density distribution in the tissue, while the absorption μa, beyond 
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contributing to determine the light pattern, indicates unspecific absorption of photons, which 
does not induce any photochemical effect. It is worth noting that most of the dosimetry 
studies assume that the absorption spectrum of the photosensitizer is the one measured from 
injectable solutions or in simple biological models, like micelles or similar systems. 
Nevertheless, it has been found that the interaction of photosensitizers with the biological 
substrate can lead to an in vivo spectrum that cannot be predicted on the basis of in vitro 
studies. The following section deals with a time resolved technique that can be used to 
measure the actual absorption spectrum of sensitizers upon intravenous injection in mice. 
14.2.1 Absorption spectra of photosensitizers measured in vivo 
The optical properties of tissues and exogenous substances administered for diagnostic or 
therapeutic purposes may be influenced by functional state, metabolism, blood perfusion, and 
so on. Therefore in vitro measurements could lead to an inaccurate spectrum. This problem 
can be avoided by means of time-resolved reflectance, which allows one to determine the 
optical properties (absorption and scattering coefficients) of tissues in vivo (Patterson et al. 
1989, Cubeddu et al. 1994a). This can be easily done in anesthetized mice, but could be 
theoretically performed in humans as well, since the procedure is completely non invasive. 
Hereafter, only measurements made on mice are reported. 
To this purpose, short (picoseconds) light pulses generated by a laser tuneable over a wide 
spectral range (e.g. 600–700 nm) are delivered to an anesthetized mouse through an optical 
fiber. The light travelling inside the animal, and partially remitted by its surface, is collected 
by a second fiber placed few millimeters apart (e.g., 1 cm). The distal end of the fiber is 
coupled to a fast Photomultiplier Tube (PMT) whose output is processed by a Time 
Correlated Single Photon Counting (TCSPC) apparatus. 
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Photons undergo multiple scattering and absorption inside the tissue. This results in 
broadening and shaping of the laser pulses in such a way that the remitted light carries 
information about the absorption (μa) and scattering (μs) coefficients of the part of the tissue 
that is traversed by photons. Assuming an ideally short input pulse (Dirac delta function), the 
output pulse, measured by the TCSPC apparatus, gives the Temporal Point Spread Function 
(TPSF) of the overall system, including the response of the experimental equipment and the 
properties of the analyzed sample. It can be demonstrated that, by fitting the TPSF with a 
proper mathematical model for photon propagation in turbid media, convoluted with the 
response of the experimental system, the dependencies of the equipment can be removed and 
the optical parameters of the sample (μa and μs) can be recovered. In most cases, the 
mathematical model used to predict the photon migration inside the tissue relies on the 
diffusion equation, with proper boundary conditions. This assumes that photons lose 
information about their original direction after traveling a distance (about 1 mm or less) that 
corresponds to few mean free paths. Thereafter, they behave like heat diffusing in a 
homogeneous medium. 
Coming back to the problem of estimating the absorption properties of photosensitizers in 
vivo, a differential measurement is performed (Cubeddu et al. 1994b). Actually, by scanning 
the laser wavelength all over the spectral range of interest, the absorption coefficient μa of 
anesthetized animals is measured twice, as a function of the wavelength, before and after the 
injection of a therapeutic dose of the sensitizer. The true absorption spectrum of the sensitizer 
is then recovered through a simple difference between the acquired spectra, in such a way that 
the absorption properties of tissue are removed. 
Insert Fig. 4 here 
 18 
Experiments performed on mice after the injection of 25 mg/kg body weight (b.w.) of HpD 
showed that the absorption spectrum of HpD measured in the range 600-640 nm (Fig. 14.4) 
has a peak close to 620 nm. This is in good agreement with the spectrum measured in a 
solution of HpD bounded to Low Density Lipoproteins (LDL), which simulated the biological 
environment. This result demonstrates that the absorption properties of HpD are not 
remarkably modified, at least in the 600-640 nm range (which is of interest for PDT), by 
interactions with the biological substrate that may occur only in vivo. It is worth noting that 
the described method, besides providing the true spectrum of the sensitizer in vivo, also 
estimates the increase in the absorption caused by the accumulation of the drug in the tissue. 
This resulted to be close to 20% for the specific case considered in this study. The 
simultaneous measurement of scattering and absorption properties leads to the knowledge of 
the penetration depth of light in tissue. This allows one to determine the optimal light dose for 
therapeutic purposes, while the measurement of the absorption lineshape yields the optimal 
irradiation wavelength. 
Different from what reported for HpD, measurements performed following the same 
protocol on the absorption spectrum of disulphonated Aluminum phthalocyanine (AlS2Pc) 
showed a marked difference with respect to the absorption spectrum measured in aqueous 
solution. 
Phthalocyanines have been considered as possible second generation photosensitizers for 
PDT (MacDonald and Dougherty 1999). AlS2Pc shows an absorption spectrum peaked at 
672 nm or red-shifted of no more than 4 nm in various solution environments. Nevertheless, 
experiments on the action spectrum for PDT in tumor-bearing mice resulted in a good 
therapeutic efficacy for wavelengths greater than 670 nm and up to 710 nm, in a range where 
the absorption measured in solution decreases rapidly (Canti et al. 1992).  
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Insert Fig. 5 here 
Actually, the absorption spectrum of AlS2Pc measured by time-resolved reflectance in the 
650-695 nm range in tumor-bearing mice (dose  = 2.5 mg/ml b.w.) peaks at 685 nm instead of 
672 nm (Fig. 14.5) (Cubeddu et al. 1996). This red-shift with respect to the absorption 
maximum in solution is consistent with the therapeutic efficacy in the treatment of tumor 
models that proved to be significantly better at 685 nm than at 672 nm. 
The spectral change seems to indicate a strong interaction between the sensitizer and the 
biological substrate. A modification of the chemical structure can perhaps be speculated, since, 
as above-mentioned, various solvents and environments (e.g. micelles) could never lead to 
such a remarkable red-shift of the AlS2Pc absorption spectrum. 
This result highlights the importance of the in vivo measurement of the optical properties 
of drugs whenever the interaction with light is a key element for activation, as it is the case of 
PDT. 
14.2.2 Time-gated fluorescence imaging of photosensitizers in tumor-bearing mice  
14.2.2.1. In vivo studies 
Fluorescence spectroscopy and imaging offer effective opportunities for cancer diagnosis, 
which are being carefully investigated since long ago (Wagnières et al. 1998). Fluorescence 
techniques are minimally invasive, relatively inexpensive with respect to other diagnostic 
methodologies, and can be easily applied to any part of the human body that can be reached 
by light, either directly or by means of an endoscope. In diagnostic procedures, fluorescence 
can in principle provide the clues for the detection of several disorders, and in particular 
tumors. Yet, unfortunately, a broadband emission is a general characteristic of both cancerous 
and non-cancerous tissues. Therefore, the mere presence of a fluorescence signal often 
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provides only a limited diagnostic aid. In order to increase the specificity for tumor detection, 
the exogenous emission of suitable markers can be considered. To this purpose, great 
attention has been devoted to photosensitizers originally developed to treat tumors with PDT. 
Some photosensitizers are also promising for diagnosis, since they accumulate in cancerous 
tissues with a good selectivity, are fluorescent and, last but not least, have already been 
approved for human administration (as described in Section 14.1). 
To exploit exogenous fluorescence for tumor diagnosis, a selectivity criterion is needed to 
discriminate the emission of the fluorophore of interest from the background signal, which is 
mainly due to tissue autofluorescence. The discrimination can be obtained in the spectral 
domain by selecting two suitable excitation or observation wavelengths (Andersson-Engels et 
al. 1991). The subtraction between the images acquired at the two wavelengths leads to an 
image that mainly contains the contribution of the fluorophore of interest. However, this 
technique requires a non-trivial normalization; moreover the fluorescence spectra of organic 
compounds often overlap, reducing the selectivity of the spectral approach. Using a pulsed 
excitation, various events characterized by a different time scale, take place. Such events, like 
scatted light and emission of different fluorophores, may be discriminated with a properly 
gated acquisition. 
Most intensified CCD-cameras allow very fast electronic gating, almost equivalent to a fast 
shutter with an exposure time of few nanoseconds or even less. Using such a device, it is 
possible to acquire only the fluorescence light that falls within a definite time window, 
properly delayed with respect to the excitation pulses. Taking into account the (multi-
)exponential behavior of the fluorescence decays, a suitable combination of gate width and 
delay provides an effective discrimination amongst fluorophores having lifetimes that differ at 
least by few nanoseconds. To apply this time-gated fluorescence imaging technique no 
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narrowband filters are required. Moreover, the images show the fluorophore localization 
without any image processing, being the selectivity intrinsic in a single acquisition process. 
This feature led to the development of a tumor detection technique capable of providing good 
selectivity and real-time operation at a time when the computer performances were several 
orders of magnitude worse than now. 
Time-gated fluorescence imaging was devoted, since the beginning, to the detection of 
cancer through the labeling of tissues with photosensitizing drugs. Hereafter, a synthetic 
review is reported of time-gated imaging performed on tumor-bearing mice sensitized with 
different drugs. 
It has been already observed (Section 14.1) that all clinically-approved photosensitizers 
used in PDT are porphyrin-based drugs. The detection of tumors on the basis of the 
Hematoporphyrin Derivative (HpD) fluorescence dates back to the Sixties (Lipson et al. 
1961). In fact, HpD, when excited at 405 nm (Soret band), emits a strong fluorescence with a 
multi-component relaxation dynamics, resulting in an average lifetime of about 15 ns, 
whereas tissue autofluorescence mainly extinguishes within 3-6 ns. This large difference in 
the decay time of the two emission components is well suited for the application of the time-
gated approach. Assuming a preferred localization of HpD in the tumor, the neoplasia can be 
easily singled out by acquiring the fluorescence of the suspected portion of tissue after a delay 
greater than 15 ns with respect to the excitation pulses. In fact, such an image will record 
almost exclusively the long living HpD emission, with a negligible contribution from 
autofluorescence. 
Insert Fig. 6 here 
This paradigm was tested on mice bearing experimental tumors implanted intraderma 
(Cubeddu et al. 1993). Mice received an intravenous injection with different doses of HpD (5-
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25 mg/kg b.w.) and underwent a fluorescent measurement after an uptake time of 12 hrs, 
required for the drug to preferentially localize in the tumor. Figure 14.6a shows a time-gated 
image acquired after a delay of 20 ns with respect to 1 ns long excitation pulses at 405 nm. 
The gate width was 50 ns, long enough to collect most of the HpD fluorescent emission. For 
comparison, Fig. 14.6b shows the same field of view observed synchronously with the 
excitation pulses. This arrangement simulates a CW acquisition. The excitation light was 
removed in both cases with a spectral filter. The tumor, which corresponds to the bright spot, 
can be distinguished more easily in the delayed image, as expected due to the selective 
acquisition of the exogenous signal and the effective rejection of the background fluorescence 
with the delayed gate. It is worth noting that the tumor was clearly detected in spite of the 
screen action of the skin against light penetration. 
Insert Fig. 7 here 
A second set of experiments was performed on mice injected with a second generation 
photosensitizer, i.e. AlS2Pc (Cubeddu et al. 1997a). In that case, the excitation light was set to 
650 nm, while the detection was at 670 nm, through a high pass spectral filter. The red 
excitation light gave two advantages with respect to the blue/violet light used to excite HpD: a 
deeper penetration in tissues and a strong reduction of the autofluorescence. However, being 
the excitation wavelength not far from the detection one, a simple high pass filter revealed to 
be insufficient to eliminate the strong laser light scattered by the sample, which is orders of 
magnitude greater than the fluorescence signal. In this case, the acquisition delay was set to 
≈1-2 ns in order to remove the scattered laser light, which was by far the greatest source of 
noise, since the endogenous fluorescence excited in the red was almost negligible. Figure 
14.7a shows the tumor area of a mouse treated with Phthalocyanine acquired with delay of 
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2 ns. For comparison, Fig. 14.7b was acquired at zero delay. The improvement in contrast is 
evident, thus demonstrating the superior performance of the gated acquisition over the CW 
one. 
14.2.2.2. Ex vivo studies 
The application of the time-gated imaging to the detection of tumors in locations other than 
the dermis represents a natural extension of this technique. A prerequisite for reliable tumor 
detection is the knowledge of the fluorescence properties, after porphyrin sensitization, of 
healthy organs, which may represent the peritumoral tissue. 
Measurements of the fluorescence of selected tissues (skin, bone, bowel, brain, muscle, 
lymph node) in tumor-bearing mice were performed after the administration of HpD or 
Photofrin II (Cubeddu et al. 1995). The emissions from different tissue types were compared 
to that of the tumor using the time-gated approach (30 ns delay) for image acquisition. The 
animals were sacrificed and dissected; the tumor with the surrounding skin was removed and 
its fluorescence was measured from the dermal side. Tissue samples of muscle, fat, brain, 
lymph nodes, bowel, and bone were excised and their fluorescence was measured as well. 
Insert Fig. 8 here 
The average intensity measured in different organs, as a function of the drug dose, is 
shown in Fig. 14.8. The strongest fluorescence was observed from the tumor through the 
inner mucosa (dermal side). The fluorescence of lymph node, fat, and muscle only differ in 
intensity, while presenting a similar dependence on the drug dose. The most fluorescent tissue 
in this group is lymph node, whose intensity is 0.4 times that of the tumor. The fluorescence 
signal of the fat is intermediate, whereas the signal recorded from the muscle is appreciably 
lower (< 0.2 times that of the tumor). The fluorescence of the bowel partially depends on the 
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mouse feed and deceases with uptake time (data not shown). Hence, the contrast with respect 
to the tumor is rather high after 12 hrs.  
The fluorescence of the bone in control animals is by far higher than that of other tissues 
and it is more than half the fluorescence of bone in sensitized animals. Finally the 
fluorescence of the brain is negligible for all the examined animals due to the blood-brain 
barrier that prevents drug uptake. 
The signal detected in the tumor is very high, yet also the fluorescence of the derma, which 
in this model is the peritumoral tissue, is remarkable. Better contrast could be expected with 
peritumoral tissues other than skin.  
Time resolved spectra taken in all the examined tissues confirmed that the only 
fluorophore with a long lifetime is the sensitizer.  
From the diagnostic standpoint, the rather high fluorescence observed in adipose tissues 
and in bones could be misinterpreted and cause false positives. This is especially true for 
bones due to the long lifetime emission that is naturally present in the tissue. As a 
consequence of this endogenous emission, the fluorescence intensity of bones can compete 
with that of the tumor, mainly at low dose of sensitizer. The awareness of this possible 
mistake should suggest particular care to avoid any wrong or uncertain diagnosis. 
In summary, it can be affirmed that, except for bones, the endogenous fluorescence does 
not impair the tumor detection by the time-gated imaging technique, whose reliability is 
strictly related to the selectivity of the drug. 
As conclusive remarks, it is worth noting that the time-gated imaging technique provides 
several interesting features for cancer detection after sensitization with exogenous compounds, 
mainly porphyrin based ones. Amongst them: real time operation, complete removal of laser 
excitation light and operation under ambient light, since the synchronous acquisition 
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effectively removes any CW illumination. On the other hand, it requires a pulsed laser and a 
rather expensive gated camera. 
14.2.3 Fluorescence lifetime imaging of photosensitizers in tumor-bearing mice  
In the previous Section, we observed that the concentration of HpD in the peritumoral 
tissue is often not negligible. The ratio of fluorescence intensity in the tumor to the intensity 
in the nearby tissues is dose-dependent and sets a lower limit to the drug dose that is required 
for reliable tumor detection using porphyrins. 
It is well known that the time-resolved emission of HpD presents three main components, 
having different lifetimes and amplitudes. Moreover, the biological environment influences 
the fluorescence properties of the drug. This observation suggests one to study the spatial 
distribution of the HpD fluorescence decay time in sensitized mice, with the aim to 
discriminate tumor from healthy tissue. 
Fluorescence lifetime imaging (FLIM), which is the natural evolution of time-gated 
imaging, is the preferred option for cancer detection through exogenous sensitization. To fully 
understand its effectiveness, the fluorescence lifetime maps of the HpD fluorescence was 
measured in tumor-bearing mice as a function of the drug dose (Cubeddu et al. 1997b). Mice 
bearing a fibrosarcoma (MS-2, diameter of ∼6 mm) on the back were injected intra-
peritoneally with the following HpD doses: 0.1, 0.25, 1, 2.5, and 10 mg/kg b.w.. The highest 
dose was considered for comparison with time-gated imaging (see previous Section). A very 
simple approach, consisting in the acquisition of only two images delayed by 10 and 30 ns 
with respect to the excitation pulses, allows one to measure the map of the effective lifetime 
in the field of view, in a very short time. In fact, the acquisition of the images take a fraction 
of a second and the image processing is also very fast since only algebraic functions are 
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required to recover the lifetime. Moreover, since the first delay is longer than the typical 
decay time of the endogenous fluorescence, the lifetime map is minimally affected by the 
endogenous emission of the tissues. 
Insert Fig. 9 here 
Figure 14.9a, shows the fluorescence lifetime map of the back of a mouse sensitized with 
0.25 mg/kg body weight of HpD. The tumor boundaries are clearly outlined in the time 
domain map, since the neoplasia corresponds to a fluorescence lifetime longer than that of the 
healthy tissue. On the contrary, an intensity based fluorescence image, which is shown in Fig. 
14.9b for comparison, is much less effective for tumor detection. It is worth noting that Fig. 
14.9b displays only the exogenous fluorescence since it has been acquired 20 ns after the 
excitation. Fluorescence images taken at zero delay are even worse, since the tissue natural 
fluorescence completely masks the drug signal, leading to useless images. A similar result 
was achieved with all the drug doses, but the highest one. In fact, even though the FLIM 
technique still works at high dose, delayed intensity images also allow a reliable detection of 
the neoplasia, as already observed in the previous Section. As an example, Figs. 14.10a and 
14.10b show a decay time image and an intensity image respectively, of the back of a mouse 
sensitized with 10 mg/kg b.w. of HpD. 
Insert Fig. 10 here 
It is worth noting that the lifetime measured by means of this technique does not represent 
any true physical parameter. However, it gives a diagnostic index resulting from a weighted 
average of the lifetimes of the different HpD fractions that localize in tumor and healthy 
tissues.  
As a matter of fact, the imaging study indicates that the HpD fluorescence emission is 
characterized by a longer lifetime when incorporated into neoplastic tissues. This is in 
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agreement with the dependence on the environment typically observed for various 
photophysical properties of HpD.. In particular, as described in Subsection 14.1.4.1, HpD and 
its commercial version Photofrin are mixtures of porphyrin monomers and different types  of 
oligomers. Monomers and oligomers have different fluorescence properties for what concerns 
both the emission spectrum and the corresponding lifetimes. The tumor-localizing fraction 
consists mostly in oligomers, thus different fluorescence properties are expected from tumors 
as compared to healthy tissues. 
14.3. Fluorescence imaging of photosensitizers in humans 
14.3.1 Detection of skin lesions by fluorescence imaging 
As described in Subsection 14.1.4.3, a very special photosensitizer is δ-aminolevulinic acid 
(ALA), which is a naturally occurring precursor in the cycle of heme biosynthesis (Kennedy 
et al. 1990). The exogenous administration of this substance bypasses a physiologic 
regulation mechanism and gives rise to an excess of the intermediate molecule Protorphyrin 
IX (PpIX), which is photoactive and strongly fluorescent. Even though this process takes 
place also in healthy tissue, in cancerous tissue it is more effective due to enhanced uptake of 
ALA and enzymatic deficiencies occurring in neoplastic cells. This unbalance in the content 
of PpIX provides a selectivity criterion that can be profitably exploited not only for PDT, but 
also to detect tumors by means of fluorescence techniques. In fact, PpIX, when excited with 
light at 400 nm, emits a characteristic red fluorescence (peaking around 635 nm) with lifetime 
of about 18 ns, i.e. much longer than that of the endogenous tissue fluorescence (3-6 ns or 
shorter). 
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Topical administration of ALA allows the patient to avoid skin sensitization. It is 
especially suitable for the detection of exposed pathologies, like skin tumors, even though 
pigmented lesions, like the very aggressive melanoma, cannot be detected by fluorescence 
imaging because no appreciable emission can be revealed from these strongly absorbing 
lesions. This not withstanding, a great interest exists in dermatology for the classification of 
lesions that present a different degree of malignancy. In addition, a technique capable of 
showing the actual extent of the pathologic area would allow surgeons to perform 
conservative excisions, while reducing the recurrence rate. In the following, we will report on 
the use of fluorescence lifetime imaging to distinguish basal cell carcinomas and squamous 
cell carcinomas from benign lesions (Cubeddu et al. 1999). 
The excitation light is provided by a dye laser pumped by a sub-nanosecond Nitrogen laser. 
The laser emission peaks around 400 nm with average power of 800 µW. Such a power level 
does not raise any safety concern and allows one to perform the diagnostic procedure even on 
the patient’s head, close to the eyes. This is very important since most dermatological lesions 
are on parts of the body exposed to sunlight and in particular on the face. An optical fiber is 
used to deliver the light to the patient, while the fluorescence signal is collected using a high 
aperture photographic lens. The system was designed in such a way that even non-technical 
personnel can operate it for routine clinical examinations. 
The diagnostic procedure involves the preparation of an ointment made of 2% ALA 
powder in a lipid emulsion. The ALA ointment is applied onto the lesion with a margin of at 
least 10 mm in the visibly normal skin and the lesion is covered with an occlusive dressing. 
The patient is kept at rest for about 1 hr to allow the metabolism to transform ALA into PpIX. 
Then, the excess cream is gently removed from the lesion and the fluorescence test is carried 
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out. A preliminary examination is performed using only two gated images. In this case the 
map of the fluorescence lifetime is calculated in real time using an algebraic equation and 
displayed in pseudocolors at few frames per second. Then, for the regions that present a 
clinical relevance, a more precise measurement is performed by acquiring more images with 
delays ranging from 0 to 20 ns, relative to the excitation pulses. The images are processed 
offline immediately after the acquisition to calculate the maps of the average fluorescence 
lifetime and of its amplitude.  
The classification of the lesions from fluorescence images is made according to the 
following considerations. It is proved that the malignant character of a skin lesion is 
associated with an excess of exogenous fluorescence and a reduction in natural emission, as 
compared to healthy tissues. As a consequence, the average lifetime in tumors is longer that in 
healthy tissues since the amplitude of the long living component (PpIX fluorescence) is 
higher than that of the short living emission (endogenous fluorescence). The use of the 
fluorescence lifetime as a diagnostic index, instead of intensity or spectral features, gives 
additional advantages. In fact, the detection index is based on the relaxation dynamics of the 
fluorescence emission. Hence, it is almost insensitive to artifacts due to the spatial variation 
of the fluorescence intensity. In particular, the time domain approach gets rid of an uneven 
distribution of the excitation light and - most important - of local differences in skin 
absorption. These may be due to anomalies in pigmentation, vascularization, or blood 
perfusion, due to an inflammatory status, which might lead to severe artifacts if one looks at 
the fluorescence intensity. Finally, the diagnostic procedure can be carried out under normal 
illumination. 
Insert Fig. 11 here 
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Thirty-four patients affected by 48 lesions, either malignant (mainly basal cell carcinomas) 
or benign ones, were included in the study considered hereafter. For all the patients, the 
classification of the lesions on the basis of fluorescence lifetime maps was compared to 
histology, which was routinely performed. A typical fluorescence lifetime image of a 
malignant lesion is shown in Fig. 14.11a, while the map of the CW fluorescence intensity is 
displayed in Fig. 14.11b. For comparison, the color photo of the lesion is also reported in Fig. 
14.11c. The tumor, which was classified as a basal cell carcinoma, is characterized by a 
significantly longer lifetime (18 ns) than that of the surrounding healthy tissue (≈10 ns). It is 
worth noting that the region where the ALA ointment was applied is larger than the lesion 
itself and can be easily distinguished in Fig. 14.11a. The fluorescence amplitude is lower in 
the lesion, as expected. However, the clinical experience demonstrates that, while the 
fluorescence amplitude presents a strong variability from patient to patient, the lifetime is 
much more stable and thus reliable for the classification of the lesions. In the present trial, 27 
out of 35 malignant lesions were correctly identified, while only 1 out of 13 benign lesions 
was misinterpreted. On the basis of these outcomes, the diagnostic procedure showed a 
sensitivity of 88% and a specificity of 74%. However, it is very important to observe that the 
test was not conducted according to a strictly blind protocol. Hence, the results are only 
indicative. Actually, it has been reported that the typical PpIX red fluorescence can be directly 
observed on the skin lesions of ALA-sensitized patients under CW excitation. This is 
certainly true only when the marker dose is rather high. When the ALA dose is reduced to few 
percents in the ointment, as it is required in a minimally invasive diagnostic protocol, the 
interference of the natural skin fluorescence and the uneven pigmentation prevent reliable 
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lesion identification by means of an intensity-based approach. In such a condition the lifetime 
technique exhibits its maximum effectiveness as it has been previously shown. 
14.3.2 Fluorescence imaging of brain tumors 
Brain tumors, either primary or resulting from metastasis, are amongst the most aggressive 
neoplastic diseases. In particular, gliomas account for a large fraction of all primary brain 
tumors and are characterized by high morbidity. In fact, in almost all but very few patients, 
such a tumor leads to inevitable death within a relatively short time after diagnosis. Moreover, 
treatment of gliomas poses a challenge due to their tendency to infiltrate the surrounding 
normal brain and to a high rate of recurrence.  
The most common treatment of gliomas is surgery followed by chemotherapy and 
radiation therapy. It has been observed that the extent of tumor resection plays a significant 
role in patient prognosis and disease progression, resulting in the most important factor for 
longer survival. Nevertheless, the extent of resection compares with the need to minimize the 
removal of normal brain, which might result in neurological impairment and affect the 
patient’s quality of life. Although of paramount importance, complete tumor resection is 
limited by the difficulty in visually detecting differences between normal brain and malignant 
tissue during surgery. Thus, patients with malignant gliomas often have a subtotal resection.  
As a consequence, there is a pressing need to develop new strategies to improve the 
intraoperative imaging of malignant glioma. To this purpose, fluorescence imaging of brain 
tumor during surgery has been extensively studied since long ago (Moore et al. 1948). Yet, it 
was not until the last decades when the technological advancement and the advent of ALA–
PpIX sensitization fostered this research field toward a widespread use. This led to 
multicentre clinical trials, mainly performed in Germany (Stummer et al. 2006), while other 
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clinical efforts were carried out in Japan focusing on a different class of markers (i.e., 
fluorescein labeling) (Kuroiwa et al. 1998, Shinoda et al. 2003). 
More generally, in a wealth of studies, either experimental or clinical ones, three major 
labeling strategies exploiting fluorescence emerged for brain tumor imaging, with a different 
degree of maturity (Pogue et al. 2010): endogenous fluorophores (autofluorescence); 
exogenous agents that are routinely used in humans (e.g., ALA-PpIX, fluorescein, 
indocyanine green); exogenous agents developed for first-time use in humans, with molecular 
targeting potential. 
Autofluorescence does not require the administration of any drug. The signal is largely 
attributed to collagen, nicotinamide adenine dinucleotide (NADH), flavin adenine 
dinucleotide (FAD) and endogenous porphyrins. Yet, it is usually very dim and imposes a 
rather long acquisition time, which might hamper surgical procedures. Moreover, 
fluorescence images can be affected by artifacts cased by blood and scattered light. Different 
strategies, mainly based on spectral ratios, have been devised to gain specificity for tumor 
tissue versus normal one. However, the reliability of the autofluorescence approach for tumor 
demarcation is still critical and site dependent. 
The ALA–PpIX system has been extensively studied for PDT and photodiagnosis, 
including fluorescence-guided resection of brain tumors (Stummer et al. 2000). In fact, a 
significant accumulation of PpIX has been found in brain tumors, mainly high grade gliomas, 
even if a still detectable PpIX emission chracterizes also low grade gliomas, meningiomas and 
brain metastases. (a Valdés et al. 2011).  
Other low molecular weight markers, like Sodium Fluorescein or Indocyanine Green, have 
been studied for tumor labeling, because they are retained within tumor tissue as a result of 
 33 
slow clearance. In particular, fluorescein labeling of brain tumors dates back to the Forties 
(Moore et al. 1948) and has been applied even recently in Japan (Kuroiwa et al. 1998).  
Finally, functionalized nanoparticles, and other molecular probes providing active tumor 
targeting are intensively studied for tumor detection, but are still not used in clinical 
applications due to safety concerns. 
From the technological point of view, several devices were proposed for brain tumor 
demarcation, ranging from point-like spectroscopes, to modified surgical microscopes and 
commercial systems with built-in fluorescence channels. Laser-induced fluorescence 
spectroscopy has been used since long time ago for diagnosis of brain cancer. Most of the 
measurements were performed under steady state excitation. Yet, in the last years time-
resolved spectroscopy of several types of brain tumors demonstrated the potential of this 
strategy on patients. In particular, a recent study (Butte et al. 2011) showed that time-resolved 
fluorescence holds the potential to diagnose brain tumors intra-operatively and to provide a 
valuable tool for aiding the neurosurgeon to rapidly distinguish between tumor and normal 
brain tissue.. 
Point like spectroscopy proved very effective to detect biochemical differences in tissues 
leading to diagnostic outcomes; yet, the choice of the measurement site requires a priori 
information or clear clues of the disease in the operation field. This is not always the case, 
mainly close to the tumor margins. Time is a precious resource during surgery and imaging 
devices are certainly preferred over point like instruments, since they can provide an 
immediate view of critical areas. Moreover, the margins between tumor and healthy tissue 
could be displayed in real time, thus giving the surgeon an effective guidance. Amongst 
imaging devices, the ones based on the time-resolved approach, like FLIM, provide extra 
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valuable features, like good immunity versus unspecific absorbers (e.g., blood) and uneven 
excitation patterns.  
The first attempt to develop a FLIM system for fluorescence-guided brain resection was 
recently made by Sun and coworkers (Sun et al. 2010), exciting with a nitrogen laser and 
detecting the endogenous fluorescence with a gated CCD coupled to a fiber optic endoscope. 
Even if the results of the study were still preliminary, they suggest that a FLIM assisted 
surgical microscope could be very beneficial for conservative brain surgery with a high 
degree of selectivity for tumor. Such a device would certainly result in an increase in patient 
survival time.  
As the reader has likely noted from what reported here above, none of the attempts to the 
fluorescence imaging of the brain made up to now has combined exogenous markers with 
time domain detection. The advantages of either of the two approaches were demonstrated on 
patients separately, but they have not been combined yet. 
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14.5. Figure captions 
Figure 14.1 – Type I vs Type II photosensitization reactions. P: Photosensitizer; S: Substrate.  
 
Figure 14.2 – Jablonsky diagram showing excitation and de-excitation transitions. A1 (A2): 
absorption to the first (second) excited singlet state; F: fluorescence; IC: internal conversion; 
VR: vibrational relaxation; ISC: intersystem crossing; P: phosphorescence.  
 
Figure 14.3 – Porphyrin (left) and phthalocyanine (right) structure. 
 
Figure 14.4 – Absorption line shape of HpD measured in vivo in tumor-bearing mice (25 
mg/kg b.w.) (■) and in LDL (10 µM HpD in 0.3 mg/mL LDL) (solid line). 
 
Figure 14.5 – Absorption line shape of 2.5 mg/kg b.w. AlS2Pc measured in vivo in tumor-
bearing mice () and 10 µg/ml AlS2Pc in aqueous solution (solid line). 
 
Figure 14.6 – Fibrosarcoma on the back of a mouse treated with 10 mg/kg b.w. of HpD 12 
hrs before the experiment: (a) image acquired using a 20-ns delay after the excitation pulses; 
(b) image acquired synchronously with the excitation. 
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Figure 14.7 – Fibrosarcoma on the back of a mouse treated with 5 mg/kg b.w. of AlS2Pc 3 
hrs before the experiment: (a) image acquired using a 2-ns delay after the excitation pulses; 
(b) image acquired synchronously with the excitation. 
 
Figure 14.8 – Average fluorescence intensity of tumor, fat, bowel, muscle, lymph node, bone 
and dermis. 
 
Figure 14.9 – Decay time image (a) and time gated image (b) of a tumor on the back of a 
mouse sensitized with 0.25 mg/kg b.w. of HpD. 
 
Figure 14.10 – Decay time image (a) and time gated image (b) of a tumor on the back of a 
mouse sensitized with 10 mg/kg b.w. of HpD. 
 
Figure 14.11 – Fluorescence lifetime map (a) and intensity image (b) of a basal cell 
carcinoma on the cheek, 1 h after the topical administration of 1% ALA cream. The color 
image of the lesion is also shown (c). 
